2/25
08:38 pm
fbio
Fortress Biotech's Cyprium enters agreement to sell PRV for $205M [Yahoo! Finance]
Low
Report
Fortress Biotech's Cyprium enters agreement to sell PRV for $205M [Yahoo! Finance]
2/23
11:23 am
fbio
Fortress Biotech (NASDAQ:FBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
Medium
Report
Fortress Biotech (NASDAQ:FBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
2/23
09:55 am
fbio
UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million [Yahoo! Finance]
High
Report
UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million [Yahoo! Finance]
2/23
09:24 am
fbio
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
High
Report
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
2/23
08:48 am
fbio
Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million [Yahoo! Finance]
High
Report
Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million [Yahoo! Finance]
2/23
08:30 am
fbio
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Medium
Report
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
2/23
08:00 am
fbio
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
Low
Report
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
1/18
08:21 am
fbio
Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Less Than A Year Away From Profitability [Yahoo! Finance]
Medium
Report
Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Less Than A Year Away From Profitability [Yahoo! Finance]
1/16
07:20 am
fbio
Fortress Biotech (NASDAQ:FBIO) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
Fortress Biotech (NASDAQ:FBIO) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
1/13
07:45 am
fbio
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
High
Report
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
12/15
08:10 am
fbio
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission [Yahoo! Finance]
Medium
Report
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission [Yahoo! Finance]
12/15
08:00 am
fbio
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
High
Report
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
12/9
04:24 pm
fbio
Fortress Biotech (NASDAQ:FBIO) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Fortress Biotech (NASDAQ:FBIO) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.